156
Registered trials
76
Recruiting
59
Completed trials
82
Sponsors
23
Countries
Phase III:
67
Phase II/III:
12
Phase II:
53
Phase I/II:
11
Phase III/IV:
3
Phase IV:
8
Phase I (Other):
1
Phase I (FiH):
1
Oversight events:
7 serious breaches
11 temporary halts
2 urgent safety measures
8 unexpected events
1 corrective measure
across 19 trials
View oversight register →
Indications tested
Triple negative breast cancer
9
Breast cancer
6
Colorectal cancer stage III
4
Gastric cancer
4
Colorectal cancer metastatic
4
Colorectal cancer
4
Hormone receptor positive breast cancer
3
Colorectal cancer stage II
3
Metastatic gastric cancer
3
Breast cancer metastatic
3
HER2 positive breast cancer
3
Hormone receptor positive HER2 negative breast cancer
3
Sponsors using this IMP
Merck Sharp & Dohme LLC
13
AstraZeneca AB
12
Unicancer
8
Fondation Franc.Cancerologie Digestive
6
Fondazione GONO G.I.
6
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
6
IRCCS Istituto Nazionale Tumori Fondazione Pascale
6
Bristol-Myers Squibb Services Unlimited Company
4
Centre Hospitalier Universitaire Rouen
4
HUS-Yhtymae
3
Amsterdam UMC
2
Amsterdam UMC Stichting
2
All trials — page 3
156 totalShowing 49–72 of 156 trials